In addition to being closely related to inflammatory pain, the MAPK/ERK/NF-κB pathway is abnormally activated in EMs; therefore, inhibiting the MAPK/ERK pathway may be a viable option for the treatment of Ems.21–23 A previous study has suggested that the MAPK pathway is hyperactivated in EMs. Here, NFKB1 is linked to eosinophilia-myalgia syndrome.